Abbott Laboratories
ABT
$123.62
-$1.05-0.84%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.98B | 13.98B | 13.50B | 13.40B | 5.77B |
| Total Depreciation and Amortization | 3.13B | 3.14B | 3.17B | 3.22B | 3.22B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.14B | 1.14B | 1.14B | 1.16B | 802.00M |
| Change in Net Operating Assets | -9.13B | -9.22B | -8.86B | -9.22B | -1.07B |
| Cash from Operations | 9.12B | 9.04B | 8.95B | 8.56B | 8.73B |
| Capital Expenditure | -2.20B | -2.26B | -2.29B | -2.21B | -2.24B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -85.00M | -30.00M | -- | -- | 0.00 |
| Divestitures | 0.00 | 0.00 | 1.00M | 1.00M | 1.00M |
| Other Investing Activities | -88.00M | -220.00M | -91.00M | -132.00M | -55.00M |
| Cash from Investing | -2.38B | -2.51B | -2.38B | -2.34B | -2.30B |
| Total Debt Issued | 4.00M | 5.00M | 224.00M | 223.00M | 244.00M |
| Total Debt Repaid | -2.16B | -1.63B | -1.67B | -760.00M | -1.11B |
| Issuance of Common Stock | 416.00M | 439.00M | 417.00M | 264.00M | 273.00M |
| Repurchase of Common Stock | -906.00M | -1.35B | -1.35B | -1.30B | -1.24B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.04B | -3.97B | -3.91B | -3.84B | -3.77B |
| Other Financing Activities | -82.00M | -82.00M | -- | -- | -- |
| Cash from Financing | -6.77B | -6.59B | -6.28B | -5.40B | -5.60B |
| Foreign Exchange rate Adjustments | -18.00M | 28.00M | -36.00M | -96.00M | 12.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -47.00M | -36.00M | 248.00M | 720.00M | 849.00M |